INIS
adhesion
6%
anticoagulants
15%
apoptosis
5%
applications
32%
atherosclerosis
19%
biological markers
17%
blood
5%
blood cells
39%
boron 19
6%
comparative evaluations
29%
complement
11%
concentration
8%
control
5%
data
15%
death
7%
dimers
19%
diseases
10%
doses
6%
emergencies
15%
hemolysis
7%
in vitro
19%
kinases
62%
levels
7%
lymphomas
15%
macrophages
6%
matrices
15%
migration
8%
molecules
6%
morphology
6%
myeloid leukemia
35%
neutrophils
15%
origin
7%
patients
100%
phospholipids
21%
plasma
26%
production
22%
reagents
15%
reviews
51%
risks
32%
ruptures
15%
sensitivity
9%
storage
15%
thrombin
28%
thrombosis
18%
transfusions
8%
tyrosine
62%
variations
6%
viability
7%
Medicine and Dentistry
Acute Leukemia
18%
Acute Myeloid Leukemia
15%
Biological Marker
18%
Cancer Cell
5%
Cell Adhesion Molecule
5%
Cell Function
15%
Cell Survival
15%
Chronic Myelogenous Leukemia
17%
D-Dimer
15%
Dasatinib
18%
Disseminated Intravascular Coagulation
15%
Drug Resistance
13%
Edoxaban
15%
Emergency Department
15%
Endothelial Cell
18%
Erythrocyte
7%
Erythrocyte Concentrate
15%
Hemophagocytosis
15%
HL60
15%
Imatinib
12%
In Vitro
15%
Independent Reviewer
7%
Leukemia Cell
15%
Meta-Analysis
15%
microRNA
15%
Morphology
9%
Multidrug Resistance
15%
Multidrug Resistance Protein 1
7%
Myelodysplastic Syndrome
15%
Neutrophil
15%
Nilotinib
10%
Paroxysmal Nocturnal Hemoglobinuria
15%
Phospholipid
5%
Ponatinib
11%
Procoagulant
31%
Systematic Review
15%
Thrombin
11%
Thrombosis
31%
Tyrosine-Kinase Inhibitor
31%
Venous Thromboembolism
17%
Keyphrases
Acute Myeloid Leukemia Cells
15%
Age-adjusted Cutoff
15%
Arterial Events
11%
Atherosclerosis Plaque
15%
BCR-ABL Inhibitors
15%
Chronic Myeloid Leukemia
15%
Cytogenetic Abnormalities
6%
D-dimer
15%
Del(20q)
15%
Direct Oral Anticoagulants
15%
Edoxaban
15%
Emergency Department
15%
Erythrophagocytosis
15%
Fibrous Cap
5%
Leukemia Patients
15%
Longitudinal Clinical Study
15%
Major Molecular Response
15%
Morphological Characteristics
6%
Myelodysplasia
15%
Myelodysplastic Syndrome
9%
Neutrophils
15%
Nilotinib
6%
Plaque Rupture
15%
Platelet-free Plasma
8%
Ponatinib
6%
Prospective Longitudinal Study
15%
Red Cell Concentrates
15%
Vascular Occlusive Events
11%
Vesicle Production
6%